An interventional study of Video in Prostate Cancer, sponsored by M.D. Anderson Cancer Center. Recruiting at 1 site in United States. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-26.
Sponsored by M.D. Anderson Cancer Center · Not applicable, Interventional, and Health services research
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 124 studies in Prostatic Neoplasms by M.D. Anderson Cancer Center — 22 open to participants now, 40 under way, 3 of them phase 3. Prostatic Neoplasms · M.D. Anderson Cancer Center.
Among the 124 studies in Prostatic Neoplasms by M.D. Anderson Cancer Center, this one is the 43rd largest by planned enrollment of the 106 interventional ones that give a count, is one of 4 that started in 2026, is one of 25 with no phase, reaches primary completion later than 24 of the 39 other live ones, and was the 123rd registered.
7,058 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.
Browse Prostatic Neoplasms studies →22 of the 124 studies in Prostatic Neoplasms by M.D. Anderson Cancer Center are open now, in 1 country. Recruiting first, the newest first:
M.D. Anderson Cancer Center · Sites in United States
Ages 18+ · Men only
M.D. Anderson Cancer Center · Sites in United States
Ages 18+ · Men only
M.D. Anderson Cancer Center · Sites in United States
Ages 18+ · Men only
M.D. Anderson Cancer Center · Sites in United States
Ages 18+ · Men only
M.D. Anderson Cancer Center · Sites in United States
Ages 18+ · Men only
By country, each count listing its studies:
Of the 1,236 Prostatic Neoplasms studies recruiting now, 933 (75%) set no upper age limit and 77 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.
This study: 18 Years and older · male · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
124 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 23 · Phase 2 56 · Phase 3 8 · Phase 4 2
First in 1996; this study’s year is marked. 4 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 60 is close to the median of 60 across 5,358 interventional studies indexed under Prostatic Neoplasms.
Median enrollment 41 across the 106 interventional studies, 123 across the 18 observational. Of the 65 that completed or were terminated, 23 (35%) have results posted.
This tab as a report to print or save as PDF → With an account.
M.D. Anderson Cancer Center is the lead sponsor of 3,051 studies on the registry; 580 are open to participants now.
Of its 614 completed or terminated interventional studies of FDA-regulated products, 409 (67%) have results posted.
17 of the studies in Prostatic Neoplasms by M.D. Anderson Cancer Center that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06274047Phase 3M.D. Anderson Cancer CenterPROSTATE-IQ: Parallel RandOmized STudy of Personalized Apalutamide Treatment and Evaluation to Improve Quality of Life in Post-Operative Radiation With Androgen Axis Suppression. A Phase III Multi-center Study for Men With Detectable PSA After Prostatectomy for Prostate Cancer. | 2027-06-30 |
| NCT03987386Phase 3M.D. Anderson Cancer CenterConventional or Hypofractionated Radiation Therapy in Treating Patients With Prostate Cancer | 2027-11-01 |
| NCT04388852M.D. Anderson Cancer CenterDS3201 and Ipilimumab for the Treatment of Metastatic Prostate, Urothelial and Renal Cell Cancers | 2026-12-31 |
| NCT06066437M.D. Anderson Cancer CenterNeoAdjuvant Theranostic Lutetium Study: The Nautilus Trial | 2026-12-31 |
| NCT05873192M.D. Anderson Cancer CenterPresurgical Phase II Study of Talazoparib in Combination With Enzalutamide in Prostate Cancer | 2026-12-31 |
Add all 17 to your calendar (.ics) → With an account.
Among the 124 studies in Prostatic Neoplasms by M.D. Anderson Cancer Center, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The main rationale underlying this study is that prostate cancer clinical trials are lacking representation from racial and ethnic minority groups. Study proposal aims to target barriers at the participant, investigator, and health system level through specific interventions to increase the percentage of participants from these backgrounds on cancer clinical trials.
Primary Objectives:
The study objective is to increase the number of participants on prostate cancer clinical trials at LBJ. Investigators will complete several objectives:
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
These criteria include diagnosed prostate cancer patients receiving care at LBJ Hospital who
Are eligible for an open prostate cancer clinical trial at LBJ Hospital during the study period
Can provide .
Exclusion Criteria:
These criteria include prostate cancer patients receiving care at LBJ who are unable to participate due to a serious psychological or cognitive condition or have a medical condition that prevents participation in the trial.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The interventions will be conducted at Lyndon B. Johnson (LBJ) Hospital, a safety net facility that cares for a majority Latino and/or Black patient population.
Other: Video
The investigator will conduct multiple one-hour educational sessions focused on participant-centered communication and cultural competency with the 42 oncology fellows during their academic half-days. Fellows attending the educational sessions will be invited to complete a Likert-style course evaluation form and provide open-ended feedback."
Other: Video
Participants will watch a short video in clinic. Participants will complete the two validated scales before and after viewing the video.
Safety and Adverse Events (AEs)
Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version (v) 5.0
Time frame: Through study completion; an average of 1 year
Started May 2026 (actual). Primary completion is estimated for Jan 2028, 20 months after the start.
Of 1,104 non-industry interventional studies with no phase under Prostatic Neoplasms, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 87. This study's planned 20 months is below that.
Counting every sponsor, half of 1,162 studies reached it within 43 months; a quarter within 22 and three quarters within 86.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.